REGISTERED NUMBER: |
FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2023 |
FOR |
CW PHARMA CONSULTANTS LTD |
REGISTERED NUMBER: |
FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2023 |
FOR |
CW PHARMA CONSULTANTS LTD |
CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251) |
CONTENTS OF THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 31 AUGUST 2023 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 3 |
CW PHARMA CONSULTANTS LTD |
COMPANY INFORMATION |
FOR THE YEAR ENDED 31 AUGUST 2023 |
DIRECTOR: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Chartered Accountants |
115c Milton Road |
Cambridge |
CB4 1XE |
CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251) |
BALANCE SHEET |
31 AUGUST 2023 |
2023 | 2022 |
Notes | £ | £ |
CURRENT ASSETS |
Debtors | 4 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 5 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
CAPITAL AND RESERVES |
Called up share capital |
Retained earnings |
SHAREHOLDERS' FUNDS |
The director acknowledges his responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered. |
The financial statements were approved by the director and authorised for issue on |
CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251) |
NOTES TO THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 31 AUGUST 2023 |
1. | STATUTORY INFORMATION |
CW Pharma Consultants Ltd is a |
The presentation currency of the financial statements is the Pound Sterling (£). |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
Taxation |
Taxation for the year comprises current tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Pension costs and other post-retirement benefits |
Payments in respect of other post-retirement benefits are charged to profit or loss in the period to which they relate. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
4. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Other debtors |
5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Trade creditors |
VAT | 7,290 | 4,638 |
Director's current account | 277,781 | 375 |
Accruals |
CW PHARMA CONSULTANTS LTD (REGISTERED NUMBER: 08525251) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE YEAR ENDED 31 AUGUST 2023 |
6. | RELATED PARTY DISCLOSURES |
Aston Pharmaceuticals Limited |
As at the balance sheet date, the company was owed £155,822 (2022 - £141,656) by Aston Pharmaceuticals Limited. There are no fixed repayment terms in place. Interest of £14,166 (2022 - £5,167) has been charged on the outstanding amount. |
Meta Healthcare Limited |
As at the balance sheet date, the company was owed £351,583 (2022 - £104,031) by Meta Healthcare Limited. There are no fixed repayment terms in place. Interest of £14,552 (2022 - £8,031) has been charged on the outstanding amount. |
Vantage Pharmaceuticals Limited |
As at the balance sheet date, the company was owed £94,315 (2022 - £41,696) by Vantage Pharmaceuticals Limited. There are no fixed repayment terms in place. Interest of £7,619 (2022 - £1,696) has been charged on the outstanding amount. |
7. | ULTIMATE CONTROLLING PARTY |
The ultimate controlling party is |